Pixium Vision SA
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh. Pixium Vision SA was founded in 2011 and is based in Paris, France.
Show More
CEO
Dr. Bernard Gilly Ph.D.
Employees
40
Country
France
ISIN
FR0011950641
WKN
000A3EJJQ
Listings
0 Comments
Share your thoughts
FAQs
What is Pixium Vision SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Pixium Vision SA stocks are traded under the ticker PXH.MU.
How many employees does Pixium Vision SA have?▼
As of November 2, 2026, the company has 40 employees.
In which sector is Pixium Vision SA located?▼
Pixium Vision SA operates in the Health & Wellness sector.
When did Pixium Vision SA complete a stock split?▼
The last stock split for Pixium Vision SA was on September 21, 2023 with a ratio of 1:50.
Where is Pixium Vision SA headquartered?▼
Pixium Vision SA is headquartered in Paris, France.